Changing phenotypic expression in a patient with a mitochondrial encephalopathy due to 13042G>A de novo mutation—a 5 year follow up

M. Schinwelski · B. Kierdaszuk · J. Dulski · K. Tońska · A. Kodroń · E. J. Sitek · E. Bartnik · A. Kamińska · H. Kwieciński · J. Slawek

Received: 30 September 2014 / Accepted: 8 December 2014 / Published online: 31 December 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract Mutations in NADH dehydrogenase (ND) subunits of complex I lead to mitochondrial encephalomyopathies associated with various phenotypes. This report aims to present the patient’s clinical symptomatology in the context of a very rare 13042G>A de novo mutation and with an emphasis on changing phenotypic expression and pronounced, long-standing response to levetiracetam.

Keywords Encephalomyopathy · Mitochondrial diseases · Mitochondrial Encephalopathy with Lactic Acidosis and Stroklike episodes · Levetiracetam · Myoclonic Epilepsy with Ragged Red Fibres

Mutations in NADH dehydrogenase (ND) subunits of complex I lead to mitochondrial encephalomyopathies associated with various phenotypes (Lim et al. 2009). We have recently described a 13042G>A de novo mutation in a patient with an overlapping mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) and myoclonic epilepsy with ragged red fibres (MERRF) clinical features. Genotyping for common mitochondrial mutations was negative, but clinical phenotype and the muscle biopsy suggested a mitochondrial disease. Thus, further genetic testing was performed and revealed a very rare 13042G>A mutation (Slawek et al. 2012). This report aims to present the patient’s clinical symptomatology in the context of a rare mutation and with an emphasis on pronounced and long-standing response to levetiracetam (LVT).

A 26-year-old Caucasian male, with unremarkable family history, was asymptomatic until the age of 18 when myoclonic jerks of the right upper extremity appeared followed by persistent headache, nausea and vomiting. At the age of 20 generalized (probably secondary) epileptic seizures occurred. Valproate administration increased number of seizures and he was switched to oxcarbazepine (600 mg BID), which resulted in remission of seizures.

Neurological examination at the age of 21 showed myoclonic jerks of the right upper extremity appeared followed by persistent headache, nausea and vomiting. At the age of 20 generalized (probably secondary) epileptic seizures occurred. Valproate administration increased number of seizures and he was switched to oxcarbazepine (600 mg BID), which resulted in remission of seizures.

Laboratory studies performed at the age of 22 showed a normal serum lactic acid level of 9.45 mg% with an abnormal lactic acid curve during ischaemic...
muscle exercise. Creatine kinase activity was within the normal range. A 50 min video EEG disclosed a pattern characteristic for myoclonic epilepsy. Visual evoked potentials showed delayed P100 responses. Electromyography and nerve conduction studies were within normal ranges. Magnetic Resonance Imaging (MRI) showed multifocal hyperintensive lesions on T2 and FLAIR images in the right cerebral peduncle, close to the occipital horns of the lateral ventricles, in the left temporal lobe as well as in both frontal and parietal lobes (Fig. 1, segment a and b). Additionally, Magnetic Resonance Spectroscopy (MRS) indicated elevated lactate levels within the previously specified areas.

The myoclonic jerks of upper limbs persisted despite the oxcarbazepine treatment. Therefore at the age of 22 the treatment was changed to levetiracetam 2 g daily with an excellent outcome—myoclonic movements significantly diminished (Unified Myoclonus Rating Scale score decreased from 69 to 18 points after 2 months). The patient’s quality of life improved dramatically and he was able to continue his education at the Technical University (see Video, Segment 2).

Improvement after LVT was seen over 36 months until other symptoms (beside myoclonic jerks) significantly handicapped our patient. At the age of 26 (5 years after the initial examination) he presented with generalized choreatic movements, exotropia in the right eye, vertical gaze limitation (especially downgaze), increased tendon reflexes on the left side, broad-based unsteady gait, dis-equilibrium and generalized ataxia. Ophthalmological examination revealed significant progression of optic nerve atrophy. A routine MRI scan showed new T2-weighted hyperintensities bilaterally in the thalamus and brainstem, which corresponded with the observed deterioration of the patient’s neurological status (Fig. 1, segment c, d) (see Video, Segment 3).

Mild cognitive dysfunction was stable at follow-up neuropsychological examinations at the age of 24 and 26. However, emotional deficits (leading to breakdown of relationships) and anosognosia progressed over time. The patient denied any psychological problems and failed to recognize the implications of motor symptoms (e.g. he continued to drive and engage in risky physical activity, unadjusted to his health state, ignoring medical recommendations).

During 5 years observation of the patient with de novo 13042 G>A mutation in subunit ND5 of mitochondrial complex I (CI) and overlapping symptomatology of MELAS, MERRF, PEO (progressive external ophthalmoplegia) and finally of LHON (Leber’s hereditary optic neuropathy) was noticed. Recently, there has been increased interest in the DNA gene encoding subunit 5 of complex I (MT-ND5), as a mutation hot spot for several overlap syndromes (Blok et al. 2007). Although 13042G>A mutation was described earlier by Naini et al. (2005), we present a patient with a de novo mutation and long-term follow-up. This long-term observation shows the very complex pattern of neurological abnormalities evolving during 5 years from epilepsy, myoclonus and dystonia to choreatic movements with ophthalmoplegia and optic neuropathy.

In conclusion we suggest levetiracetam as a good symptomatic treatment of disabling myoclonus.

Acknowledgments EJS received a scholarship for young researchers from the Polish Ministry of Science and Higher Education during the preparation of this manuscript.

Conflict of interest All authors declare no conflict of interest and the presented case study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Furthermore all authors declare that the submitted work has not been published before (neither in English nor in any other language) and that the work is not under consideration for publication elsewhere.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
References

Blok MJ, Spruijt L, de Coo IF, Schoonderwoerd K, Hendrickx A, Smeets HJ (2007) Mutations in the ND5 subunit of complex I of the mitochondrial DNA are a frequent cause of oxidative phosphorylation disease. J Med Genet 44(4):e74

Lim BC, Park JD, Hwang H, Kim KJ, Hwang YS, Chae JH, Cheon JE, Kim IO, Lee R, Moon HK (2009) Mutations in ND subunits of complex I are an important genetic cause of childhood mitochondrial encephalopathies. J Child Neurol 24(7):828–832

Naini AB, Lu J, Kaufmann P et al (2005) Novel mitochondrial DNA ND5 mutation in a patient with clinical features of MELAS and MERRF. Arch Neurol 62:473–476

Slawek J, Kierdaszuk B, Tonska K, Kodron A, Schinwelski M, Sitek EJ, Bartnik E, Kaminska A, Kwiecinski H (2012) Mitochondrial encephalopathy in a patient with a 13042G>A de novo mutation. J Clin Pathol 65:1147–1149